Get the app
USHealthcare

West Pharmaceutical Services Inc (WST)

US · Healthcare · Medical Instruments & Supplies

$366.60+1.27%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$872.3M
Revenue YoY
+13.8%
Net profit
$154.0M
Profit YoY
+16.8%
EPS
$2.37
EPS estimate
$2.08
Net margin
17.7%

EPS came in at 2.37 against a street estimate of 2.08 — a beat of 13.9%.

Key statistics

Market cap
$25.48B
P/E
46.7
Forward P/E
36.5
P/B
8.59
Book value
$42.47
EPS (TTM)
$7.75
Dividend yield
0.24%
52-week high
$385.75
52-week low
$223.52
50-day MA
$348.89
200-day MA
$296.57
Beta
1.14

Analyst view

Analysts rate West Pharmaceutical Services Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $405.38.

Shareholding

Insiders
0.66%
Institutions
101.95%

Largest institutional holders

FundStake
BlackRock Inc9.71%
Vanguard Capital Management, LLC6.65%
Vanguard Portfolio Management, LLC5.82%
State Street Corp4.68%
Bank of New York Mellon Corp3.50%
Artisan Partners Limited Partnership3.43%
T. Rowe Price Investment Management,Inc.3.33%
Generation Investment Management LLP2.88%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
WEST PHARMACEUTICAL SERVICES, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Sales (6 months): $1,717.2 million vs. $1,464.5 million in 2025 (+1
2026-07-23
Results announced · Q3 2026
WEST PHARMACEUTICAL SERVICES, INC. — Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $872.3 million, up 13.8% reported and 12.7% orga
2026-07-23
Material agreement · Q3 2026
WEST PHARMACEUTICAL SERVICES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company entered into renewed agreements with Daikyo Seiko, Ltd. effective J
2026-07-14
Board / officer change · Q2 2026
WEST PHARMACEUTICAL SERVICES, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • New CEO compensation package total: approximately $28.7 million over initia
2026-06-01
Reg FD disclosure · Q2 2026
WEST PHARMACEUTICAL SERVICES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Material cybersecurity attack detected May 4, 2026; company formally determ
2026-05-11
Quarterly report · Q1 2026
WEST PHARMACEUTICAL SERVICES, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $844.9 million (Q1 2026) vs. $698.0 million (Q1 2025) — incr
2026-04-23
Proxy statement · Q2 2026
WEST PHARMACEUTICAL SERVICES, INC. – PROXY SUMMARY FOR RETAIL INVESTORS CEO TOTAL COMPENSATION AND CHANGE • Eric M. Green (CEO) total compensation:
2026-03-12
Annual report FY2025
WEST PHARMACEUTICAL SERVICES, INC. – FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization: $15.7 billion (as of June 30, 2025) • Outstanding s
2026-02-17

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.22 / share
ex-date Jul 29, 2026 · pay Aug 5, 2026
2026-07-29
Dividend$0.22 / share
ex-date Apr 29, 2026 · pay May 6, 2026
2026-04-29
Dividend$0.22 / share
ex-date Jan 28, 2026 · pay Feb 4, 2026
2026-01-28
Dividend$0.22 / share
ex-date Nov 12, 2025 · pay Nov 19, 2025
2025-11-12

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for West Pharmaceutical Services Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.